Aveanna Healthcare Holdings, Inc.: Form 10-Q for the period ended Sep 30, 2023
Filed with the SEC on Nov 9, 2023 and accepted by EDGAR at Nov 9, 2023, 11:13 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-07-02 to 2023-09-30 | $478.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2023-01-01 to 2023-09-30 | $1.42bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Gross profit | 3 months2023-07-02 to 2023-09-30 | $147.3m | us-gaap:GrossProfit |
| Gross profit | 9 months2023-01-01 to 2023-09-30 | $447.0m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months2023-07-02 to 2023-09-30 | $91.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2023-01-01 to 2023-09-30 | $274.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2023-07-02 to 2023-09-30 | −$76.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2023-01-01 to 2023-09-30 | −$21.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-07-02 to 2023-09-30 | $39.6m | us-gaap:InterestExpense |
| Interest expense | 9 months2023-01-01 to 2023-09-30 | $113.5m | us-gaap:InterestExpense |
| Income tax | 3 months2023-07-02 to 2023-09-30 | $631.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2023-01-01 to 2023-09-30 | $1.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-07-02 to 2023-09-30 | −$102.4m | us-gaap:NetIncomeLoss |
| Net income | 9 months2023-01-01 to 2023-09-30 | −$108.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-07-02 to 2023-09-30 | −$0.54 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2023-01-01 to 2023-09-30 | −$0.57 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-07-02 to 2023-09-30 | −$0.54 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2023-01-01 to 2023-09-30 | −$0.57 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-07-02 to 2023-09-30 | 189,139,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2023-01-01 to 2023-09-30 | 189,632,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2023-01-01 to 2023-09-30 | $25.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2023-09-30 | $48.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-09-30 | $318.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-09-30 | $1.65bn | us-gaap:Assets |
| Current liabilities | At period end2023-09-30 | $364.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-09-30 | $1.76bn | us-gaap:Liabilities |
| Long-term debt | At period end2023-09-30 | $1.28bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2023-09-30 | $9.2m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2023-09-30 | −$105.7m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-23-061484. Last ingested by Listed: Oct 24, 2026, 15:15 ET. Listed shows no prices and gives no investment advice.